Effects of genistein aglycone in glucocorticoid induced osteoporosis: A randomized clinical trial in comparison with alendronate.
Bone remodeling
Clinical trials
Genistein
Osteoporosis
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
30
01
2023
revised:
14
04
2023
accepted:
30
04
2023
medline:
29
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
ppublish
Résumé
Glucocorticoid-induced osteoporosis (GIO) complicates the clinical management of patients subjected to long-term glucocorticoid use. This study explored the effects of genistein on bone loss in a randomized double-blind alendronate-controlled trial in postmenopausal women with GIO. 200 postmenopausal women (taking at least 5 mg of prednisone equivalents) since 3 months, or more, and expected to continue for at least other 12 months, were randomized to receive genistein (54 mg/day daily) or alendronate (70 mg once a week) for 24 months. Both groups received also Calcium and Vitamin D3 supplementation. Median bone mineral density (BMD) at the antero-posterior lumbar spine significantly increased from 0.75 g/cm
Identifiants
pubmed: 37167726
pii: S0753-3322(23)00611-X
doi: 10.1016/j.biopha.2023.114821
pii:
doi:
Substances chimiques
Alendronate
X1J18R4W8P
Glucocorticoids
0
Genistein
DH2M523P0H
Bone Density Conservation Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114821Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None. Conflict of interest Francesco Squadrito and Alessandra Bitto received research grants from Primus Pharmaceuticals Inc and are listed as inventors in several patents related to Primus Pharmaceutical Inc. However, they do not retain economic benefits from the commercial use of these patents.